A randomised, double-blind, placebo-controlled, parallel-group, multicenter study comparing the efficacy and safety of 17-beta estradiol 10 micrograms and 25 micrograms (Vagifem) doses in treatment of estrogen deficiency-derived atrophic vaginitis

Trial Profile

A randomised, double-blind, placebo-controlled, parallel-group, multicenter study comparing the efficacy and safety of 17-beta estradiol 10 micrograms and 25 micrograms (Vagifem) doses in treatment of estrogen deficiency-derived atrophic vaginitis

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Mar 2017

At a glance

  • Drugs Estradiol (Primary)
  • Indications Atrophic vaginitis; Genitourinary disorders; Menopause; Vaginitis
  • Focus Therapeutic Use
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 03 Mar 2017 Last checked against ClinicalTrials.gov record.
    • 01 Jan 2008 Results have been published.
    • 07 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top